Nathaniel Katz

Summary

Affiliation: Tufts University School of Medicine
Country: USA

Publications

  1. ncbi Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy
    Nathaniel P Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Anesth Analg 97:1097-102, table of contents. 2003
  2. ncbi Challenges in the development of prescription opioid abuse-deterrent formulations
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:648-60. 2007
  3. ncbi Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology
    Nathaniel Katz
    Analgesic Research, Needham, MA, 02494, USA
    Clin J Pain 25:797-807. 2009
  4. doi Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA 02111, USA
    Pharmacoepidemiol Drug Saf 19:115-23. 2010
  5. ncbi Opioids: after thousands of years, still getting to know you
    Nathaniel Katz
    Analgesic Research, Needham, MA 02494, USA
    Clin J Pain 23:303-6. 2007
  6. ncbi A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Curr Med Res Opin 23:117-28. 2007
  7. ncbi Abuse-deterrent opioid formulations: are they a pipe dream?
    Nathaniel Katz
    Analgesic Research, 109 Highland Avenue, Suite B2, Needham, MA 02494, USA
    Curr Rheumatol Rep 10:11-8. 2008
  8. doi The impact of opioids on the endocrine system
    Nathaniel Katz
    Analgesic Research, Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 25:170-5. 2009
  9. ncbi Foundations of opioid risk management
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:103-18. 2007
  10. ncbi ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety
    Nathaniel Katz
    Tufts University School of Medicine, Boston, Massachusetts Analgesic Research, Needham, MA 02494, USA
    J Pain 11:303-11. 2010

Detail Information

Publications38

  1. ncbi Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy
    Nathaniel P Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Anesth Analg 97:1097-102, table of contents. 2003
    ..Requiring a report of behavioral issues and urine toxicology screens for patients receiving chronic opioids creates a more comprehensive monitoring system than either alone...
  2. ncbi Challenges in the development of prescription opioid abuse-deterrent formulations
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:648-60. 2007
    ....
  3. ncbi Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology
    Nathaniel Katz
    Analgesic Research, Needham, MA, 02494, USA
    Clin J Pain 25:797-807. 2009
    ..To systematically identify and critically assess clinical trials that use enriched enrollment randomized withdrawal (EERW) trial design as a methodology for assessing the effect of analgesics pain...
  4. doi Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA 02111, USA
    Pharmacoepidemiol Drug Saf 19:115-23. 2010
    ..We analyze herein 11 years of Massachusetts PMP data to evaluate trends in opioid prescribing, dispensing, and usage...
  5. ncbi Opioids: after thousands of years, still getting to know you
    Nathaniel Katz
    Analgesic Research, Needham, MA 02494, USA
    Clin J Pain 23:303-6. 2007
  6. ncbi A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Curr Med Res Opin 23:117-28. 2007
    ..Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP)...
  7. ncbi Abuse-deterrent opioid formulations: are they a pipe dream?
    Nathaniel Katz
    Analgesic Research, 109 Highland Avenue, Suite B2, Needham, MA 02494, USA
    Curr Rheumatol Rep 10:11-8. 2008
    ....
  8. doi The impact of opioids on the endocrine system
    Nathaniel Katz
    Analgesic Research, Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 25:170-5. 2009
    ..However, their negative effects on the endocrine system, which have been known for some times, are barely discussed in modern medicine. Therefore, we conducted a systematic review of the impact of opioids on the endocrine system...
  9. ncbi Foundations of opioid risk management
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:103-18. 2007
    ..Limitations of current approaches, and emerging directions in opioid risk management, are also presented...
  10. ncbi ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety
    Nathaniel Katz
    Tufts University School of Medicine, Boston, Massachusetts Analgesic Research, Needham, MA 02494, USA
    J Pain 11:303-11. 2010
    ..4; ALO-01, 2.3, P = .31), WOMAC change-from-baseline (mean pain, physical function, composite scores), and adverse event frequency were similar. ALO-01 and ERMS provided similar relief of osteoarthritis pain...
  11. doi Efficacy and safety of tanezumab in the treatment of chronic low back pain
    Nathaniel Katz
    Analgesic Solutions, Needham, MA 02494, USA
    Pain 152:2248-58. 2011
    ..Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients...
  12. ncbi Volume of prescription opioids used nonmedically in the United States
    Nathaniel P Katz
    Analgesic Research, Waltham, Massachusetts 02494, USA
    J Pain Palliat Care Pharmacother 24:141-4. 2010
    ..This estimate provides a perspective on the magnitude of prescription opioids abuse and should help policy makers enact policies that reduce prescription opioid abuse and diversion without preventing legitimate access to opioid therapy...
  13. ncbi Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Postgrad Med 122:112-28. 2010
    ....
  14. ncbi Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials
    Nathaniel Katz
    Harvard Medical School, Boston, Massachusetts 02464, USA
    Curr Med Res Opin 20:651-8. 2004
    ..The objectives of this report are to present data regarding the onset of efficacy of rofecoxib from these trials and propose methods for reporting onset...
  15. ncbi Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
    Alan G White
    Analysis Group, Inc, Boston, Massachusetts, USA
    Appl Health Econ Health Policy 7:61-70. 2009
    ..As well as public health and safety benefits, use of an abuse-deterrent/resistant RxO (ADO) that may deter abuse, dependence and misuse could also generate cost savings...
  16. ncbi Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Spine (Phila Pa 1976) 28:851-8; discussion 859. 2003
    ..Two replicate, 4-week, randomized, double-blind, placebo-controlled, trials of rofecoxib 25 and 50 mg versus placebo for chronic low back pain...
  17. ncbi Preliminary development of a responder index for chronic low back pain
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02465, USA
    J Rheumatol 34:1386-91. 2007
    ..The aim of the OMERACT Special Interest Group was to discuss the development and validation of a preliminary responder index in CLBP...
  18. doi Illustration of a statistical process control approach to regional prescription opioid abuse surveillance
    James C Benneyan
    Center for Health Organization Transformation, Northeastern University, Boston, MA, USA
    J Addict Med 5:99-109. 2011
    ..To investigate and illustrate the use of statistical process control (SPC) for prospective monitoring and detection of regional changes in prescription opioid abuse rates...
  19. ncbi Role of urine toxicology testing in the management of chronic opioid therapy
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin J Pain 18:S76-82. 2002
    ..The authors conclude that, although further research is urgently needed, at this time it is appropriate to conduct routine urine toxicology testing in patients with chronic pain treated with opioids...
  20. ncbi Methodological issues in clinical trials of opioids for chronic pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Neurology 65:S32-49. 2005
    ..Opioid analgesics should be studied in a manner that is clinically relevant, and that supports internal validity. More systematic attention is needed to clinical research methodology...
  21. ncbi Direct costs of opioid abuse in an insured population in the United States
    Alan G White
    Analysis Group, Inc, 111 Huntington Ave, 10th Fl, Boston, MA 02199, USA
    J Manag Care Pharm 11:469-79. 2005
    ..g., inpatient, outpatient, emergency room, drug, other) from the perspective of a private payer...
  22. ncbi Coxibs: Evolving role in pain management
    Nathaniel Katz
    Department of Anesthesia, Harvard Medical School, Boston, MA, USA
    Semin Arthritis Rheum 32:15-24. 2002
    ..Decreased GI and antiplatelet effects of coxibs compared to traditional NSAIDs provide the potential to incorporate coxibs into the pain management algorithm used to treat cancer pain...
  23. pmc Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control study
    Corey M Bieber
    Inflexxion, Inc, Newton, MA, USA
    Exp Clin Psychopharmacol 16:429-34. 2008
    ....
  24. ncbi Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective
    Howard G Birnbaum
    Analysis Group, Inc, Boston, MA 02199, USA
    Clin J Pain 22:667-76. 2006
    ..This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States...
  25. doi Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions
    Nathaniel Katz
    Analgesic Solutions, Natick, MA, USA
    Am J Drug Alcohol Abuse 37:205-17. 2011
    ..Transdermal and solid oral prescription opioid (PO) formulations can be abused by ingesting (with or without tampering), snorting, or injection (both requiring tampering)...
  26. doi Ultrasound-enabled topical anesthesia for pain reduction of phlebotomy for whole blood donation
    Christopher P Stowell
    Department of Pathology, Blood Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Transfusion 49:146-53. 2009
    ..Ultrasound-facilitated delivery of topical anesthetics has been used to achieve effective anesthesia within 5 minutes for venipuncture and the insertion of intravenous access devices, but has never been studied for blood donation...
  27. ncbi The impact of pain management on quality of life
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Pain Symptom Manage 24:S38-47. 2002
    ....
  28. ncbi Comparative study of electronic vs. paper VAS ratings: a randomized, crossover trial using healthy volunteers
    Robert N Jamison
    Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Pain 99:341-7. 2002
    ..Multivariate analyses showed equivalent stimuli to be rated much the same whether entered on paper VAS or PTC touch screen VAS (P < 0.0001). Support was found for the validity of the computer version of the VAS scale...
  29. ncbi Neuropsychological effects of long-term opioid use in chronic pain patients
    Robert N Jamison
    Department of Anesthesiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Pain Symptom Manage 26:913-21. 2003
    ....
  30. ncbi Analytic models to identify patients at risk for prescription opioid abuse
    Alan G White
    Analysis Group, Inc, 111 Huntington Ave, 10th Fl, Boston, MA 02199, USA
    Am J Manag Care 15:897-906. 2009
    ..To assess the feasibility of using medical and prescription drug claims data to develop models that identify patients at risk for prescription opioid abuse or misuse...
  31. ncbi A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy
    Steven D Passik
    Symptom Management and Palliative Care Program, Markey Cancer Center, University of Kentucky, 800 Rose Street, CC449, Lexington, KY 40536 0093, USA
    Clin Ther 26:552-61. 2004
    ..During long-term treatment, this assessment should focus on a broad range of outcomes, each of which should be documented in the medical record...
  32. ncbi Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool
    Steven D Passik
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Opioid Manag 1:257-66. 2005
    ..e., addiction or diversion) in only approximately 10 percent of cases. Using the PADT physician ratings can be developed in four domains. In this sample, outcomes suggested that opioid therapy provided meaningful analgesia...
  33. ncbi Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Pain 9:105-21. 2008
    ..Provisional benchmarks for identifying clinically important changes in specific outcome measures that can be used for outcome studies of treatments for chronic pain are proposed...
  34. ncbi Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP)
    Hammam Akbik
    Department of Anesthesiology, University of Cincinnati, Ohio, USA
    J Pain Symptom Manage 32:287-93. 2006
    ..Preliminary support was found for the internal reliability and predictive validity of the SOAPP. Current limitations of the SOAPP and future directions for change are discussed...
  35. doi Two-minute skin anesthesia through ultrasound pretreatment and iontophoretic delivery of a topical anesthetic: a feasibility study
    Egilius L H Spierings
    MedVadis Research Corporation, Wellesley Hills, Massachusetts, USA
    Pain Med 9:55-9. 2008
    ..We compared it with sham-ultrasound pretreatment and with standard, 10-minute high-voltage (4 mA) iontophoresis...
  36. ncbi Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
    Dennis C Turk
    Department of Anesthesiology, University of Washington, Seattle, WA 98195, USA
    Pain 106:337-45. 2003
    ....
  37. ncbi Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device
    Nathaniel P Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Anesth Analg 98:371-6, table of contents. 2004
    ..There were no significant adverse effects. Low-frequency ultrasound pretreatment appears to be safe and effective in producing rapid onset of EMLA cream in this model, with results as early as 5 min...
  38. ncbi Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Pain 113:9-19. 2005